New partnership to develop schizophrenia treatments
Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Search
antibiotic resistance one health veterinary medicine
Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
On two wheels for more animal health
Cowtribe’s social entrepreneurs win Boehringer Ingelheim's Accelerator Program.
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Supporting Rabies Free Pakistan Indus Hospital
Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
Henke-Sass Wolf develop needle free device
Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
Survey with Ipsos to gain insights human-animal bond
Boehringer Ingelheim partnered with the Ipsos Research Institute to carry out a survey to explore the human-animal bond.
Approval for Aservo EquiHaler equine asthma therapy
Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
The power of patient advocacy in cancer care
Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Facts about the INPULSIS™ trials
Our partners Bioveta
Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Boehringer Ingelheim advances SIRP immune-oncology program
Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Access to Healthcare Strategy Sustainable Access Models
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
GARC Louis Nel interview on global rabies control
GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
Boehringer Ingelheim and GST prepared bring innovation to equine market
Boehringer Ingelheim and Global Stem Cell Technology are prepared to bring groundbreaking innovation to equine market
Inauguration of new global center for veterinary vaccine R&D
Inauguration of a new global hi-tech centre for biological research and development in Lyon.
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
Open Innovation at Boehringer Ingelheim
Learn more about how we’re working across the innovation community to advance research and accelerate the development of new medicines
One step further in fighting rabies in Vietnam
A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages.
On the road with sanitation workers in India
Exhaust fumes, heat, work and traffic accidents. Overcoming all these odds, the sanitation workers in India fight a daily battle.
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle